Daraxonrasib after surgery for pancreatic ductal adenocarcinoma, compared with observation alone
Tests daraxonrasib in adults after surgery for pancreatic ductal adenocarcinoma.
Plain-language title generated from the registry record
Registry title: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Key facts
- Where
- Busan and Seoul, South KoreaSee the 4 sites
- Phase
- Phase 3
Where in South Korea
- Dong-A University HospitalBusan, South KoreaTaking people
- Asan Medical CenterSeoul, South KoreaTaking people
- Samsung Medical CenterSeoul, South KoreaTaking people
- Seoul National University HospitalSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT07252232EU 2025-523495-23-00
- Record updated
- 23 October 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.Read full original descriptionShow less
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Inclusion: At least 18 years old and has provided informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Histologically confirmed PDAC with successful (R0/R1) curative intent surgical resection and no evidence of recurrent or metastatic disease; Must have received perioperative (neoadjuvant, adjuvant, or a combination of both) multi-agent chemotherapy; Must have completed most recent treatment within the past 12 weeks; Adequate organ function (bone marrow, liver, kidney, coagulation); Documented RAS mutation status; Able to take oral medications.
Exclusion: Prior therapy with direct RAS-targeted therapy (eg. degraders and/or inhibitors); Major surgery within 28 days prior to randomization; Any conditions that may affect the ability to take or absorb study drug; Patient is unable or unwilling to comply with protocol-required study visits or procedures.